J&J leads big pharma higher after earnings despite Trump’s latest tariff threat

5 hours ago 1

Healthcare

he modern architecture of business center of Johnson and Johnson, Allschwil

After posting a double beat for Q2 2025, J&J (NYSE:JNJ), the pharma sector’s bellwether for the earnings season, added ~6% on Wednesday, marking its biggest intraday gain in nearly two years and rallying its peers despite President Trump’s latest

Recommended For You

More Trending News

Read Entire Article

J&J leads big pharma higher after earnings despite Trump’s latest tariff threat

Recommended For You

More Trending News

Related

Home BancShares Non-GAAP EPS of $0.58 beats by $0.01, revenu...

Wellfield appoints John Parker as CFO

M&T Bank lowers net interest income guidance to $7B–$7.15B a...

Earnings Snapshot: Alcoa beats Q2 revenue estimates, incurs ...

Is Mexican Coke coming to America?

Union Bankshares declares $0.36 dividend

Sequans files to sell 1.82B ordinary shares for holders

Synovus GAAP EPS of $1.48 beats by $0.22, revenue of $593.7M...

Trump says he ‘talked about the concept of firing’ Jerome Po...

Earnings Snapshot: Kinder Morgan Q2 profit rises, beats topl...

MP Materials launches $500M stock offering after surging to ...

Gladstone Investment acquires Global Grab Technologies in $6...

Regions Financial Corp Deposit Shs Repr Non-Cum Perp Pfd Shs...

Regions Financial Corporation DEPOSITARY SHS REP 1/40TH PERP...

Vornado Realty completes $450M refinancing of Penn 11

Rithm Property Trust Inc. 9.875 FXD-FLT C declares $0.6172 d...

Sarepta Therapeutics rises after restructuring, pipeline foc...

United Airlines reports mixed Q2 results as Newark disruptio...

SL Green boosts guidance after Q2 earnings, revenue beats

Earnings Snapshot: United Airlines posts mixed Q2 results, r...

Trending

Popular

بانک مرکزی: بابک زنجانی مجوز فعالیت اقتصادی ندارد

پنج مصدوم براثر تصادف پراید با دیوار در گنبدکاووس